Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Combination Details

General Information of the Combination (ID: C76406)
Name Acteoside + Paeoniflorin + X-ray irradiation
    Click to Show/Hide the Each NP or Drug Information of This Combination
Name Acteoside   NP Info     Drug Info 
Structure
Name Paeoniflorin   NP Info 
Structure
Disease
Healthy individual [ICD-11: N.A.]
Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Decreasing Adverse Drug Reaction by This Combination
                 Decreasing Adverse Drug Reaction     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [1]
                    Molecule(s)
                    Regulation
Down-regulation Expression BAX  Molecule Info 
Pathway MAP
Up-regulation Expression BCL-2  Molecule Info 
Pathway MAP
Down-regulation Expression CASP3  Molecule Info 
Pathway MAP
                    In-vitro Model Human skin fibroblasts Healthy Homo sapiens
                    Experimental
                    Result(s)
Acteoside could protect the cells from X ray induced damage through enhancing the scavenging activity of ROS, decreasing the Bax/Bcl 2 ratio and downregulating the activity of procaspase 3, as well as modulating the mitogen activated protein kinase signaling pathways.
References
Reference 1 Protective effects of acteoside against X?ray?induced damage in human skin fibroblasts. Mol Med Rep. 2015 Aug;12(2):2301-6.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China